Novonix Limited Logo

Novonix Limited

NVNXF

(1.5)
Stock Price

0,49 USD

-37.12% ROA

-47.23% ROE

-2.97x PER

Market Cap.

254.280.735,00 USD

45.27% DER

0% Yield

-651.18% NPM

Novonix Limited Stock Analysis

Novonix Limited Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Novonix Limited Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (0x), the stock offers substantial upside potential at a bargain price.

2 DER

The stock has a minimal amount of debt (17%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 Assets Growth

With continuous growth in revenue over the last five years, this company has proven to be a lucrative investment option, showcasing its strong financial performance.

4 ROE

Negative ROE (-25.26%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

5 ROA

The stock's ROA (-16.94%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

6 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

7 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

8 Graham Number

The Graham number analysis indicates that this company's stock price is likely overpriced, raising concerns about its investment potential.

9 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

10 Dividend

Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Novonix Limited Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Novonix Limited Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Hold
4 Stoch RSI Hold

Novonix Limited Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Novonix Limited Revenue
Year Revenue Growth
2015 0
2016 62.096 100%
2017 1.595.456 96.11%
2018 1.272.550 -25.37%
2019 2.922.619 56.46%
2020 3.927.501 25.59%
2021 5.790.657 32.18%
2023 8.054.528 28.11%
2024 11.102.616 27.45%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Novonix Limited Research and Development Expenses
Year Research and Development Expenses Growth
2015 0
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 4.843.133 100%
2023 5.750.574 15.78%
2024 8.209.544 29.95%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Novonix Limited General and Administrative Expenses
Year General and Administrative Expenses Growth
2015 731.889
2016 4.025.195 81.82%
2017 6.715.303 40.06%
2018 7.223.704 7.04%
2019 10.132.848 28.71%
2020 11.820.255 14.28%
2021 41.501.520 71.52%
2023 44.825.736 7.42%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Novonix Limited EBITDA
Year EBITDA Growth
2015 -954.786
2016 -4.258.771 77.58%
2017 -7.047.081 39.57%
2018 -15.326.775 54.02%
2019 -9.150.556 -67.5%
2020 -9.992.822 8.43%
2021 -41.106.947 75.69%
2023 -41.747.703 1.53%
2024 -107.146.244 61.04%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Novonix Limited Gross Profit
Year Gross Profit Growth
2015 0
2016 8.328 100%
2017 891.841 99.07%
2018 753.403 -18.38%
2019 2.067.027 63.55%
2020 3.198.874 35.38%
2021 3.722.818 14.07%
2023 5.237.259 28.92%
2024 -74.432.308 107.04%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Novonix Limited Net Profit
Year Net Profit Growth
2015 -928.844
2016 -4.714.927 80.3%
2017 -7.583.473 37.83%
2018 -18.294.193 58.55%
2019 -13.762.000 -32.93%
2020 -13.581.232 -1.33%
2021 -49.144.945 72.36%
2023 -46.248.261 -6.26%
2024 -116.317.916 60.24%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Novonix Limited Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2015 0
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Novonix Limited Free Cashflow
Year Free Cashflow Growth
2015 -14.836
2016 -1.444.137 98.97%
2017 -4.487.737 67.82%
2018 -4.123.819 -8.82%
2019 -7.418.098 44.41%
2020 -25.745.544 71.19%
2021 -107.283.994 76%
2023 -12.629.000 -749.51%
2023 -55.424.219 77.21%
2024 -32.066.767 -72.84%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Novonix Limited Operating Cashflow
Year Operating Cashflow Growth
2015 0
2016 0 0%
2017 -2.848.421 100%
2018 -2.801.417 -1.68%
2019 -3.749.257 25.28%
2020 -6.087.200 38.41%
2021 -27.759.405 78.07%
2023 -12.629.000 -119.81%
2023 -36.228.423 65.14%
2024 -22.446.678 -61.4%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Novonix Limited Capital Expenditure
Year Capital Expenditure Growth
2015 14.836
2016 1.444.137 98.97%
2017 1.639.317 11.91%
2018 1.322.402 -23.97%
2019 3.668.841 63.96%
2020 19.658.344 81.34%
2021 79.524.589 75.28%
2023 0 0%
2023 19.195.796 100%
2024 9.620.089 -99.54%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Novonix Limited Equity
Year Equity Growth
2015 2.239.848
2016 15.438.755 85.49%
2017 23.219.593 33.51%
2018 11.046.291 -110.2%
2019 45.715.664 75.84%
2020 138.543.458 67%
2021 250.635.159 44.72%
2022 226.056.269 -10.87%
2023 183.936.275 -22.9%
2024 153.260.627 -20.02%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Novonix Limited Assets
Year Assets Growth
2015 2.305.672
2016 26.108.391 91.17%
2017 25.143.347 -3.84%
2018 24.455.765 -2.81%
2019 51.710.872 52.71%
2020 152.414.252 66.07%
2021 302.378.379 49.59%
2022 277.424.558 -8.99%
2023 263.343.043 -5.35%
2024 240.387.834 -9.55%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Novonix Limited Liabilities
Year Liabilities Growth
2015 65.824
2016 10.669.636 99.38%
2017 1.923.753 -454.63%
2018 13.409.474 85.65%
2019 5.995.207 -123.67%
2020 13.870.793 56.78%
2021 51.743.219 73.19%
2022 51.368.289 -0.73%
2023 79.406.768 35.31%
2024 87.127.207 8.86%

Novonix Limited Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.03
Net Income per Share
-0.17
Price to Earning Ratio
-2.97x
Price To Sales Ratio
19.53x
POCF Ratio
-5.26
PFCF Ratio
-3.64
Price to Book Ratio
1.64
EV to Sales
21.63
EV Over EBITDA
-3.59
EV to Operating CashFlow
-5.88
EV to FreeCashFlow
-4.03
Earnings Yield
-0.34
FreeCashFlow Yield
-0.27
Market Cap
0,25 Bil.
Enterprise Value
0,28 Bil.
Graham Number
1.11
Graham NetNet
-0.07

Income Statement Metrics

Net Income per Share
-0.17
Income Quality
0.84
ROE
-0.47
Return On Assets
-0.35
Return On Capital Employed
-0.37
Net Income per EBT
1
EBT Per Ebit
0.98
Ebit per Revenue
-6.64
Effective Tax Rate
0

Margins

Sales, General, & Administrative to Revenue
1.04
Research & Developement to Revenue
0.75
Stock Based Compensation to Revenue
-0.09
Gross Profit Margin
-3.24
Operating Profit Margin
-6.64
Pretax Profit Margin
-6.54
Net Profit Margin
-6.51

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.1
Free CashFlow per Share
-0.14
Capex to Operating CashFlow
-0.46
Capex to Revenue
1.69
Capex to Depreciation
3.65
Return on Invested Capital
-0.39
Return on Tangible Assets
-0.37
Days Sales Outstanding
70.51
Days Payables Outstanding
47.36
Days of Inventory on Hand
13.48
Receivables Turnover
5.18
Payables Turnover
7.71
Inventory Turnover
27.08
Capex per Share
0.04

Balance Sheet

Cash per Share
0,10
Book Value per Share
0,31
Tangible Book Value per Share
0.29
Shareholders Equity per Share
0.31
Interest Debt per Share
0.15
Debt to Equity
0.45
Debt to Assets
0.29
Net Debt to EBITDA
-0.35
Current Ratio
6.15
Tangible Asset Value
0,14 Bil.
Net Current Asset Value
-0,03 Bil.
Invested Capital
213448231
Working Capital
0,05 Bil.
Intangibles to Total Assets
0.05
Average Receivables
0,00 Bil.
Average Payables
0,01 Bil.
Average Inventory
2016846.5
Debt to Market Cap
0.27

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Novonix Limited Dividends
Year Dividends Growth

Novonix Limited Profile

About Novonix Limited

Novonix Limited develops and supplies battery materials, equipment, and services to the lithium-ion battery market in North America. It operates through three segments: Graphite Exploration and Mining, Battery Technology, and Battery Materials. The Graphite Exploration and Mining segment explores for graphite in Australia. The Battery Technology segment develops battery cell testing equipment and batteries, and consulting services. The Battery Materials segment develops and manufactures battery anode materials. The company is also involved in the investment and battery testing activities. Novonix Limited has strategic alliance with Harper International Corporation to develop specialized furnace technology that would enhance Novonix's synthetic graphite manufacturing process; and partnership with Emera Technologies to develop and manufacture energy storage systems for community microgrids. The company was formerly known as Graphitecorp Limited and changed its name to Novonix Limited in July 2017. Novonix Limited was incorporated in 2012 and is headquartered in Brisbane, Australia.

CEO
Dr. John Christopher Burns
Employee
200
Address
Central Plaza Two
Brisbane, 4000

Novonix Limited Executives & BODs

Novonix Limited Executives & BODs
# Name Age
1 Ms. Rashda M. Buttar
Chief Legal & Administrative Officer
70
2 Mr. Robert B. Long
Chief Financial Officer
70
3 Mr. Ronald Cleve Edmonds B.B.A., CPA
Interim Executive Officer of Finance & Director
70
4 Mr. Darcy MacDougald
Chief Operating Officer
70
5 Dr. John Christopher Burns
Chief Executive Officer
70
6 Prof. Jeffrey Dahn
Chief Scientific Advisor
70
7 Lori Mcleod
President of Battery Technology Solutions
70
8 Ms. Suzanne Margaret Yeates B.Bus, C.A.
Financial Controller & Company Secretary
70

Novonix Limited Competitors